REVA CLINICS: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
REVA CLINICS
Largest movements
- Tangible fixed assets +€16,188
up €16,188 (+70.0%), from €23,133 to €39,321
of which Furniture and vehicles: +€10,119
- Receivables within one year +€2,924
up €2,924 (+37.4%), from €7,810 to €10,734
of which Trade receivables: +€4,606
- Deferred charges and accrued income +€873
new in 2025: €873
- Other debts +€27,296
up €27,296 (+72.0%), from €37,901 to €65,197
- Profit (loss) carried forward -€14,828
down €14,828 (-114.9%), from -€12,907 to -€27,735
- Trade debts +€7,333
up €7,333 (+608.6%), from €1,205 to €8,538
- Depreciation +€2,961
up €2,961 (+169.3%), from €1,749 to €4,710
- Gross operating margin +€300
up €300 (+2.9%), from -€10,300 to -€10,000
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €31,199 | €51,001 | +€19,801 | +63.5% |
| Fixed assets | 21/28 | €23,133 | €39,321 | +€16,188 | +70.0% |
| Tangible fixed assets | 22/27 | €23,133 | €39,321 | +€16,188 | +70.0% |
| Plant, machinery and equipment | 23 | €7,711 | €13,780 | +€6,069 | +78.7% |
| Furniture and vehicles | 24 | €15,422 | €25,541 | +€10,119 | +65.6% |
| Current assets | 29/58 | €8,067 | €11,680 | +€3,613 | +44.8% |
| Amounts receivable within one year | 40/41 | €7,810 | €10,734 | +€2,924 | +37.4% |
| Trade receivables | 40 | €1,957 | €6,563 | +€4,606 | +235.3% |
| Other amounts receivable | 41 | €5,853 | €4,171 | -€1,682 | -28.7% |
| Cash at bank and in hand | 54/58 | €256 | €73 | -€184 | -71.7% |
| Deferred charges and accrued income | 490/1 | - | €873 | +€873 | |
| Total equity and liabilities | 10/49 | €31,199 | €51,001 | +€19,801 | +63.5% |
| Equity | 10/15 | -€7,907 | -€22,735 | -€14,828 | -187.5% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€12,907 | -€27,735 | -€14,828 | -114.9% |
| Amounts payable | 17/49 | €39,106 | €73,736 | +€34,630 | +88.6% |
| Amounts payable within one year | 42/48 | €39,106 | €73,736 | +€34,630 | +88.6% |
| Trade debts | 44 | €1,205 | €8,538 | +€7,333 | +608.6% |
| Suppliers | 440/4 | €1,205 | €8,538 | +€7,333 | +608.6% |
| Other amounts payable | 47/48 | €37,901 | €65,197 | +€27,296 | +72.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,749 | €4,710 | +€2,961 | +169.3% |
| Other operating charges | 640/8 | €0 | - | = | |
| Gross operating margin | 9900 | -€10,300 | -€10,000 | +€300 | +2.9% |
| Operating profit (loss) | 9901 | -€12,049 | -€14,710 | -€2,661 | -22.1% |
| Financial charges | 65/66B | €49 | €118 | +€69 | +140.7% |
| Recurring financial charges | 65 | €49 | €118 | +€69 | +140.7% |
| Profit (loss) for the period before taxes | 9903 | -€12,098 | -€14,828 | -€2,730 | -22.6% |
| Profit (loss) for the period | 9904 | -€12,098 | -€14,828 | -€2,730 | -22.6% |
| Profit (loss) for the period to be appropriated | 9905 | -€12,098 | -€14,828 | -€2,730 | -22.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 12 October 2026 via checked.be.